Document Detail

The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery.
MedLine Citation:
PMID:  21478119     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The impact of drug-eluting stents (DES) has not been extensively investigated in patients with moderate to severe renal dysfunction, as these patients are consistently excluded from randomised studies. We sought to assess prospectively the effectiveness and safety of the new-generation DES in patients with moderate chronic kidney disease (CKD) and an isolated de novo lesion in the proximal segment of the left anterior descending artery (pLAD).
METHODS: We evaluated 400 consecutive patients with a pLAD lesion. There were 96 patients with moderate CKD (estimated glomerular filtration rate 59 ml/min/1.73 m2) and 304 without CKD. Major adverse cardiac events (MACE) were defined as death, non-fatal myocardial infarction and target lesion revascularisation (TLR). Clinical or telephone follow up was performed.
RESULTS: There was a significantly higher incidence of mortality in patients with CKD (n=4) as compared with non-CKD (n=2) (4.16% versus 0.65%, respectively, p=0.03). The rate of non-fatal myocardial infarction was similar in the 2 cohorts (p=0.59), as was the TLR rate (p=0.99). Overall, there were no significant differences regarding MACE between the 2 groups of patients (p=0.19) during the 13.62 ± 6.22 month follow-up period. The rate of angiographic stent thrombosis was 2.08% in the CKD group versus 0.98% in the non-CKD group (p=0.59).
CONCLUSIONS: New generation DES implantation in patients with CKD and a pLAD lesion is effective and safe, with rates of TLR and stent thrombosis comparable to those in patients with normal renal function. However, the higher mortality in patients with CKD needs further evaluation.
Konstantinos Toutouzas; Chrysoula Patsa; Andreas Synetos; Antonis Karanasos; John Karampelas; Eleftherios Tsiamis; Anastasios Spanos; Elli Stefanadi; Dimitris Tousoulis; Christodoulos Stefanadis
Related Documents :
3973939 - A prospective study of myocardial damage in electrical injuries.
7505979 - Using psa to eliminate the staging radionuclide bone scan. significant economic implica...
18281309 - Focal therapy with high-intensity-focused ultrasound in the treatment of localized pros...
12975539 - Elevated serum ca 125 levels in mitral stenotic patients with heart failure.
2659829 - High dose ketoconazole for the treatment of hormone refractory metastatic prostate carc...
20689259 - Urodynamic impact of acute urinary retention in patients with benign prostatic hyperpla...
9651689 - Percutaneous endoscopic gastrostomy in neurological rehabilitation: a report of six cases.
17481859 - Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine ...
10404709 - The effect of the first manic episode in affective disorder: a case register study of h...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē     Volume:  52     ISSN:  2241-5955     ISO Abbreviation:  Hellenic J Cardiol     Publication Date:    2011 Mar-Apr
Date Detail:
Created Date:  2011-04-11     Completed Date:  2011-09-22     Revised Date:  2013-08-07    
Medline Journal Info:
Nlm Unique ID:  101257381     Medline TA:  Hellenic J Cardiol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  103-10     Citation Subset:  IM    
First Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary*
Cohort Studies
Coronary Stenosis / complications*,  therapy*
Drug-Eluting Stents*
Immunosuppressive Agents / administration & dosage
Middle Aged
Renal Insufficiency, Chronic / complications*
Sirolimus / administration & dosage,  analogs & derivatives
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 0/zotarolimus; 159351-69-6/everolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Investigation of interaction of human platelet membrane components with anticoagulant drugs Abcixima...
Next Document:  Transradial access as first choice for primary percutaneous coronary interventions: experience from ...